RxDoctor Payments Data

Debra Lamont

Psychiatric/Mental Health · Denton, TXNPI 1043360993

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,238 of the $28,477 with a category attached, or 81.6%. AbbVie accounts for 91.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $12,158 and has fallen 99.0% since, to $126 in 2025. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,477in general payments, 2019–2025

Across 132 payments — averaging $215.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$26K
  • Validus Pharmaceuticals LLC$966
  • Alkermes, Inc.$273
  • Otsuka America Pharmaceutical, Inc.$201
  • Neurocrine Biosciences, Inc.$195
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136
  • plus $542 from 15 others

What the payments were for

  • Speaking & faculty fees$23,23882%
  • Travel & lodging$1,9127%
  • Food & beverage$3,28012%
  • Education$470%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,477 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine17$129,113
RexultiBrexpiprazole18$31,983
TrintellixVortioxetine Hydrobromide19$18,991
Clonazepam84$2,054
Bupropion XlBupropion Hcl86$2,046
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$1,373
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$1,160
Zolpidem Tartrate ErZolpidem Tartrate22$1,020
Carbamazepine12$948
Lamotrigine48$846
Paliperidone ErPaliperidone15$766
Aripiprazole41$712
Venlafaxine Hcl ErVenlafaxine Hcl15$674
Duloxetine Hcl46$658
Doxepin Hcl20$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$48$129,11317 claims
Otsuka America Pharmaceutical, Inc.Rexulti$201$31,98318 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$18,99119 claims
Almatica Pharma LLCSertraline Hcl$18$19221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →